

REMARKS

FORMAL MATTERS

Claims 1-5, 10, 14-20, 22, 27, 28 and 40 are pending after entry of the amendments set out above.

Claims 6-9, 11-13, 21, 23-26, 29-39, and 41 have been cancelled without prejudice.

Claims 1, 10, 15, 27, 28 and 40 are amended.

Claims 1 and 15 are amended to recite “wherein said signalling is capable of inducing arthritis upon administration of sera from arthritic K/BxN mice”. Support for this amendment is found in the specification at, for example, page 11, lines 16-18; page 12, line 4; page 61, lines 14-20.

Claims 10 and 27 are amended for further clarity in view of their dependency on claims 1 and 15, respectively.

Claim 28 is amended to recite screening for anti-inflammatory activity of a candidate compound in a transgenic mouse of claim 1, wherein an inflammatory response is induced in the transgenic mouse by administration of sera from arthritic K/BxN mice. Support is found in the specification at, for example, page 62, lines 17-27; and page 62, line 29 to page 63, line 7 (where the anti-human C5aR 7F3 antibody serves as an example of a “candidate compound” in this working example). See also page 39, line 32 to page 40, line 3.

Claim 40 is amended for further clarity to provide for antecedent basis for “candidate compound”.

No new matter is added.

INTERVIEW SUMMARY

Applicants thank Examiner Wilson for the telephonic interviews with the undersigned conducted on or about June 30, 2011, July 7, 2011, July 14, 2011 and July 26, 2011. During the interviews, Examiner Wilson and the undersigned discussed proposed amendments to place the claims in form for allowance. The amendments discussed are presented in this present communication.

Entry of the amendments set out above is respectfully requested.

CONCLUSION

Applicants submit that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number RICE-050.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: July 26, 2011

By: /Carol L. Francis, Reg.No.36513/
Carol L. Francis, Ph.D.
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231